Vanderbilt-Ingram Cancer Center
-
January 19, 2022
Clinical score can guide PRRT therapy decisions for neuroendocrine tumors
A clinical score system developed by researchers at Vanderbilt-Ingram Cancer Center (VICC) has been validated that can guide peptide receptor radionuclide therapy treatment decisions. -
January 5, 2022
Drug modifies epigenome in aggressive brain tumors: study
A folic acid-like drug changed a DNA process within brain tumors of glioblastoma patients, according to results from a phase 1 clinical trial. -
December 24, 2021
Study of fully vaccinated patients with cancer who had breakthrough COVID-19 shows 13% mortality rate
New research finds that fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death. -
December 14, 2021
Study sets framework for precision surveillance of colorectal cancer
Vanderbilt research has revealed some of the mechanisms by which polyps develop into colorectal cancer, setting the framework for improved surveillance for the cancer utilizing precision medicine. -
December 13, 2021
Oral microbes and gastric cancer
Studies in three large population cohorts that include Asian, African American and European American people support a role for the oral microbiota — the collection of microbial species in the mouth — in gastric cancer development. -
December 9, 2021
Cell signaling targets in leukemia
Vanderbilt researchers identified a critical role for IL-1beta signaling in leukemia cells with a certain mutation, suggesting this pathway may be a good target for novel treatments. -
December 8, 2021
New Clinician Spotlight: Kelly Hewitt
Kelly Hewitt, MD, recently joined the Division of Surgical Oncology after being recruited from St. Charles Health System in Bend, Oregon, where she served as medical director of the Breast Program.